Sales are generated predominantly from the lead product Zubsolv® for the treatment of OUD. Other revenues come from out-licensing of Zubsolv or other drugs commercialized by partners, such as Abstral® for breakthrough cancer pain and Edluar® for insomnia. Revenues from the lead product have enabled investments in research and development, including the next-generation drug delivery technology AmorphOX®. Investments in these assets are expected to generate future revenues from sales, including upfront and milestone payments, and royalty.
Business methodology
Orexo’s business model is integrated and spans from the innovation phase to product access and commercialization. Cross-functional teams bring together specialist competencies to evaluate new development projects funded by revenues from the company’s own sales or out-licensing of products and development projects.
Orexo develops pharmaceuticals meeting large medical needs and that are based on proprietary drug delivery technologies. Cross-functional teams bring together competencies in research and development, medical affairs, and business development to evaluate potential future projects. Orexo’s long experience in developing pharmaceuticals that have reached approval in markets globally has brought extensive knowledge throughout the entire development chain. Central to the development process is building a strong patent portfolio that covers all products and development projects.
The presence on the US market provides the opportunity to have regular interactions with authorities, decisionmakers, healthcare systems, insurance companies and patient organizations. In addition to pushing for decisions to be made that increase access to treatment, these interactions provide unique knowledge that is used, among other things, in the evaluation of new development projects. The sales force meets daily with private practitioners, clinics and hospitals and are an important distribution channel for reaching out with treatments to those who need them most.
Orexo’s Code of Conduct sets the basis for the sustainability work and underpins all business activities. The sustainability plan focuses on access to healthcare, employees, environment, and climate change. With its outsourced production and supply, Orexo depends on responsible suppliers and expects them to be socially and environmentally accountable based on the Supplier Code of Conduct and well-developed sustainability assessment processes.
